Thursday, October 25, 2018
Optos Plc, a subsidiary of Nikon Corporation, Japan, and the only ultra-wide-angle retinal imaging company for eye care, is pleased to announce an exclusive distribution agreement for Europe and Australia for MacuLogix and LumiThera products. By signing this agreement, we now offer a comprehensive solution to visualize, identify and treat the dry form of age-related macular degeneration (AMD), one of the leading causes of blindness in the world.
This three-part solution retains ultra-angular color and autofluorescence opto map ® images to show the structure and function of the pigmented retinal epithelium (RPE) in which DMA manifests itself in the eye. MacuLogix AdaptDx, a dark adaptometer that can be used to detect DMA at a subclinical stage at least three years before structural changes, such as drusens, are visible. And the LumiThera Valeda ™ Light Delivery System, the first approved system for the treatment of age-related macular degeneration by photobiomodulation.
"We are pleased to begin this collaboration with MacuLogix and LumiThera to fight AMD, a strategic solution for monitoring and treating AMD that is very important for patients with this complex and degenerative disease," said Robert Kennedy. CEO of Optos. "We believe these two companies have complementary products in ultra wide angle retinal imaging that could provide differentiated service for AMD patients." The MacuLogix device can enable early diagnosis of AMD and the Lumithera medical device offers a differentiated therapeutic path ".
"Optos is one of the world's largest and respected suppliers of retinal medical devices, and MacuLogix is ??very honored to conclude this international partnership with them," said William McPhee, President and CEO of MacuLogix. "By expanding our distribution network to include these eight countries, the AdaptDx will be available to an additional 260 million people.The partnership with the Optos team brings us a little closer to our corporate mission of eliminating blindness. caused by the DMA. "
Clark Tedford, Ph.D., President and CEO of LumiThera, says: "The distribution agreement with Optos allows LumiThera to begin commercialization across Europe and to establish collaboration with a partner in the field of retinal imaging Optos is the world leader in ultra-wide-angle retinal imaging technologies, and it is an honor for us to work with them to open a new chapter in the treatment of AMD. "
